MANNKIND CORP (MNKD) Fundamental Analysis & Valuation
NASDAQ:MNKD • US56400P7069
Current stock price
2.57 USD
+0.01 (+0.39%)
At close:
2.57 USD
0 (0%)
After Hours:
This MNKD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MNKD Profitability Analysis
1.1 Basic Checks
- MNKD had positive earnings in the past year.
- MNKD had a positive operating cash flow in the past year.
- In multiple years MNKD reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: MNKD reported negative operating cash flow in multiple years.
1.2 Ratios
- The Return On Assets of MNKD (0.85%) is better than 87.81% of its industry peers.
- MNKD has a better Return On Invested Capital (7.96%) than 91.88% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for MNKD is significantly below the industry average of 27.63%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.85% | ||
| ROE | N/A | ||
| ROIC | 7.96% |
ROA(3y)1.74%
ROA(5y)-9.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.85%
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of MNKD (1.92%) is better than 88.20% of its industry peers.
- Looking at the Operating Margin, with a value of 16.59%, MNKD belongs to the top of the industry, outperforming 92.65% of the companies in the same industry.
- The Gross Margin of MNKD (77.80%) is better than 84.14% of its industry peers.
- MNKD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.59% | ||
| PM (TTM) | 1.92% | ||
| GM | 77.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.37%
GM growth 5Y4.31%
2. MNKD Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MNKD is creating some value.
- The number of shares outstanding for MNKD has been increased compared to 1 year ago.
- MNKD has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for MNKD is higher compared to a year ago.
2.2 Solvency
- MNKD has an Altman-Z score of -4.22. This is a bad value and indicates that MNKD is not financially healthy and even has some risk of bankruptcy.
- MNKD has a Altman-Z score of -4.22. This is comparable to the rest of the industry: MNKD outperforms 40.23% of its industry peers.
- MNKD has a debt to FCF ratio of 44.51. This is a negative value and a sign of low solvency as MNKD would need 44.51 years to pay back of all of its debts.
- MNKD's Debt to FCF ratio of 44.51 is amongst the best of the industry. MNKD outperforms 88.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 44.51 | ||
| Altman-Z | -4.22 |
ROIC/WACC0.93
WACC8.52%
2.3 Liquidity
- A Current Ratio of 1.70 indicates that MNKD should not have too much problems paying its short term obligations.
- Looking at the Current ratio, with a value of 1.70, MNKD is doing worse than 79.88% of the companies in the same industry.
- A Quick Ratio of 1.50 indicates that MNKD should not have too much problems paying its short term obligations.
- MNKD has a worse Quick ratio (1.50) than 80.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.5 |
3. MNKD Growth Analysis
3.1 Past
- MNKD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.75%.
- The Revenue has grown by 22.23% in the past year. This is a very strong growth!
- MNKD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 39.91% yearly.
EPS 1Y (TTM)-28.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-266.67%
Revenue 1Y (TTM)22.23%
Revenue growth 3Y51.78%
Revenue growth 5Y39.91%
Sales Q2Q%45.82%
3.2 Future
- The Earnings Per Share is expected to grow by 52.44% on average over the next years. This is a very strong growth
- Based on estimates for the next years, MNKD will show a quite strong growth in Revenue. The Revenue will grow by 17.70% on average per year.
EPS Next Y-6.55%
EPS Next 2Y91.27%
EPS Next 3Y65.59%
EPS Next 5Y52.44%
Revenue Next Year36.86%
Revenue Next 2Y23.74%
Revenue Next 3Y16.07%
Revenue Next 5Y17.7%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. MNKD Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 42.83, MNKD can be considered very expensive at the moment.
- Based on the Price/Earnings ratio, MNKD is valued cheaper than 90.72% of the companies in the same industry.
- MNKD's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.78.
- The Price/Forward Earnings ratio is 48.25, which means the current valuation is very expensive for MNKD.
- MNKD's Price/Forward Earnings ratio is rather cheap when compared to the industry. MNKD is cheaper than 89.75% of the companies in the same industry.
- MNKD's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.54.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.83 | ||
| Fwd PE | 48.25 |
4.2 Price Multiples
- 94.00% of the companies in the same industry are more expensive than MNKD, based on the Enterprise Value to EBITDA ratio.
- 92.65% of the companies in the same industry are more expensive than MNKD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 57.84 | ||
| EV/EBITDA | 15.59 |
4.3 Compensation for Growth
- The decent profitability rating of MNKD may justify a higher PE ratio.
- A more expensive valuation may be justified as MNKD's earnings are expected to grow with 65.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y91.27%
EPS Next 3Y65.59%
5. MNKD Dividend Analysis
5.1 Amount
- No dividends for MNKD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MNKD Fundamentals: All Metrics, Ratios and Statistics
2.57
+0.01 (+0.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2026-02-26/bmo
Earnings (Next)05-06 2026-05-06/amc
Inst Owners58.06%
Inst Owner Change0%
Ins Owners1.57%
Ins Owner Change2.58%
Market Cap791.82M
Revenue(TTM)348.97M
Net Income(TTM)6.70M
Analysts84
Price Target7.65 (197.67%)
Short Float %7.61%
Short Ratio3.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-116.48%
Min EPS beat(2)-439.47%
Max EPS beat(2)206.52%
EPS beat(4)1
Avg EPS beat(4)-85.96%
Min EPS beat(4)-439.47%
Max EPS beat(4)206.52%
EPS beat(8)2
Avg EPS beat(8)-74.12%
EPS beat(12)5
Avg EPS beat(12)-38.6%
EPS beat(16)6
Avg EPS beat(16)-28.6%
Revenue beat(2)2
Avg Revenue beat(2)6.39%
Min Revenue beat(2)0.33%
Max Revenue beat(2)12.45%
Revenue beat(4)3
Avg Revenue beat(4)2.28%
Min Revenue beat(4)-4.55%
Max Revenue beat(4)12.45%
Revenue beat(8)6
Avg Revenue beat(8)2.33%
Revenue beat(12)9
Avg Revenue beat(12)3.51%
Revenue beat(16)12
Avg Revenue beat(16)6.12%
PT rev (1m)-21.97%
PT rev (3m)-17.18%
EPS NQ rev (1m)-164.32%
EPS NQ rev (3m)-142.9%
EPS NY rev (1m)0%
EPS NY rev (3m)-51.42%
Revenue NQ rev (1m)-1.26%
Revenue NQ rev (3m)5.83%
Revenue NY rev (1m)1.8%
Revenue NY rev (3m)11.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.83 | ||
| Fwd PE | 48.25 | ||
| P/S | 2.27 | ||
| P/FCF | 57.84 | ||
| P/OCF | 43.38 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.59 |
EPS(TTM)0.06
EY2.33%
EPS(NY)0.05
Fwd EY2.07%
FCF(TTM)0.04
FCFY1.73%
OCF(TTM)0.06
OCFY2.31%
SpS1.13
BVpS-0.17
TBVpS-1.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.85% | ||
| ROE | N/A | ||
| ROCE | 9.32% | ||
| ROIC | 7.96% | ||
| ROICexc | 10.76% | ||
| ROICexgc | 55.79% | ||
| OM | 16.59% | ||
| PM (TTM) | 1.92% | ||
| GM | 77.8% | ||
| FCFM | 3.92% |
ROA(3y)1.74%
ROA(5y)-9.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.85%
ROIC(5y)N/A
ROICexc(3y)28.62%
ROICexc(5y)N/A
ROICexgc(3y)44.91%
ROICexgc(5y)N/A
ROCE(3y)12.18%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.37%
GM growth 5Y4.31%
F-Score5
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 44.51 | ||
| Debt/EBITDA | 8.33 | ||
| Cap/Depr | 37.17% | ||
| Cap/Sales | 1.31% | ||
| Interest Coverage | 3.93 | ||
| Cash Conversion | 26.02% | ||
| Profit Quality | 204.41% | ||
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.5 | ||
| Altman-Z | -4.22 |
F-Score5
WACC8.52%
ROIC/WACC0.93
Cap/Depr(3y)368.18%
Cap/Depr(5y)300.07%
Cap/Sales(3y)8.68%
Cap/Sales(5y)9.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-266.67%
EPS Next Y-6.55%
EPS Next 2Y91.27%
EPS Next 3Y65.59%
EPS Next 5Y52.44%
Revenue 1Y (TTM)22.23%
Revenue growth 3Y51.78%
Revenue growth 5Y39.91%
Sales Q2Q%45.82%
Revenue Next Year36.86%
Revenue Next 2Y23.74%
Revenue Next 3Y16.07%
Revenue Next 5Y17.7%
EBIT growth 1Y-18.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-58.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.06%
OCF growth 3YN/A
OCF growth 5YN/A
MANNKIND CORP / MNKD Fundamental Analysis FAQ
What is the fundamental rating for MNKD stock?
ChartMill assigns a fundamental rating of 5 / 10 to MNKD.
Can you provide the valuation status for MANNKIND CORP?
ChartMill assigns a valuation rating of 5 / 10 to MANNKIND CORP (MNKD). This can be considered as Fairly Valued.
What is the profitability of MNKD stock?
MANNKIND CORP (MNKD) has a profitability rating of 6 / 10.
How financially healthy is MANNKIND CORP?
The financial health rating of MANNKIND CORP (MNKD) is 3 / 10.
Can you provide the expected EPS growth for MNKD stock?
The Earnings per Share (EPS) of MANNKIND CORP (MNKD) is expected to decline by -6.55% in the next year.